Skip to main
APGE
APGE logo

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook for Apogee Therapeutics Inc. is primarily driven by its upcoming clinical data catalysts for APG777, which is expected to solidify its best-in-class positioning in atopic dermatitis by Q1 2026. The increasing market potential is underscored by the significant sales performance of leading biologics like Dupixent, which generated over $14 billion in sales in 2024, with projections to rise to at least $20 billion, highlighting the growth opportunities for Apogee's products in a robust and expanding market. Furthermore, the anticipated advantages of APG777 over existing therapies, including improved dosing and efficacy, coupled with the proven demand for biologics in treating chronic conditions such as asthma and COPD, collectively support a promising financial trajectory for the company.

Bears say

Apogee Therapeutics Inc faces significant challenges that contribute to a negative outlook for its stock, primarily stemming from potential setbacks in its clinical development pipeline. Key risks include the possibility of unexpected safety events, weaker than anticipated efficacy, and regulatory hurdles that could halt or delay trials, severely impacting the company's ability to generate future revenues. Additionally, the company’s reliance on successful commercialization amidst a competitive landscape, combined with the absence of current revenues to support ongoing R&D, further heightens the inherent risks to its financial projections.

APGE has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Strong Buy based on their latest research and market trends.

According to 7 analysts, APGE has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.